- Home
- MAX vs PVLA Comparison
MAX vs PVLA Comparison
Compare MAX & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAX
- PVLA
- Stock Information
- Founded
- MAX 2014
- PVLA 2015
- Country
- MAX United States
- PVLA United States
- Employees
- MAX N/A
- PVLA N/A
- Industry
- MAX Industrial Machinery/Components
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- MAX Industrials
- PVLA Health Care
- Exchange
- MAX Nasdaq
- PVLA Nasdaq
- Market Cap
- MAX 551.1M
- PVLA 604.2M
- IPO Year
- MAX 2020
- PVLA N/A
- Fundamental
- Price
- MAX $11.46
- PVLA $67.95
- Analyst Decision
- MAX Strong Buy
- PVLA Strong Buy
- Analyst Count
- MAX 6
- PVLA 12
- Target Price
- MAX $18.25
- PVLA $66.67
- AVG Volume (30 Days)
- MAX 656.3K
- PVLA 182.1K
- Earning Date
- MAX 10-29-2025
- PVLA 11-15-2025
- Dividend Yield
- MAX N/A
- PVLA N/A
- EPS Growth
- MAX N/A
- PVLA N/A
- EPS
- MAX N/A
- PVLA N/A
- Revenue
- MAX $1,075,712,000.00
- PVLA N/A
- Revenue This Year
- MAX $27.91
- PVLA N/A
- Revenue Next Year
- MAX $9.49
- PVLA N/A
- P/E Ratio
- MAX N/A
- PVLA N/A
- Revenue Growth
- MAX 116.58
- PVLA N/A
- 52 Week Low
- MAX $7.33
- PVLA $11.17
- 52 Week High
- MAX $20.91
- PVLA $68.22
- Technical
- Relative Strength Index (RSI)
- MAX 45.08
- PVLA 73.66
- Support Level
- MAX $11.01
- PVLA $60.49
- Resistance Level
- MAX $11.87
- PVLA $65.57
- Average True Range (ATR)
- MAX 0.49
- PVLA 3.72
- MACD
- MAX -0.22
- PVLA 0.39
- Stochastic Oscillator
- MAX 16.61
- PVLA 98.07
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.